Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Mannkind’s Inhaled Clofazimine Will Advance To An Adaptive Phase 2 3 Study For Potential Treatment Of Rare Lung Disease is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products ... Read More
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
We recently published 12 Best Healthcare Stocks to Buy Under $30. MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)’s most recent milestone is ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus